Younghee Yun
CY Pharmaceutical Co., Ltd., South Korea
Title: Efficacy, safety and dose finding trial of topical Jaungo application in atopic dermatitis patients: a randomized, double-blind, placebo-controlled study
Biography
Biography: Younghee Yun
Abstract
Atopic dermatitis (AD) is a common pruritic inflammatory skin disease. In its chronic stage, hyperpigmentation, excoriation, lichenification, and dryness are the main symptoms. Jaungo comprises two herbs, Lithospermi radix and Angelica gigantis radix, and three carrier oils, and is an approved herbal ointment for xerosis in Korea. In past preclinical studies, we demonstrated that Jaungo had anti-inflammatory and anti-allergic activity. We conducted a randomised, double blind, placebo-controlled, single-centre trial with three parallel arms. Trial group 1 applies Jaungo twice a day, while trial group 2 applies Jaungo and the placebo once a day, separately, and the placebo group applies the placebo twice a day, for a total of 3 weeks each. Participants evaluated for eczema based on the Eczema Area and Severity score, the SCORing of Atopic Dermatitis Score, the Dermatology Life Quality score, transepidermal water loss, total IgE level, eosinophil count, and IL-17, IL-22, and IFN-γ levels. The outcomes to evaluate the safety included Draize score and blood test. In total, 28 patients (82.4%) completed the study. Significant decline of EASI scores in trial group 2 and placebo group was observed (p<0.05). There was significant decline of SCORAD scores in trial group 1 and placebo group (p<0.05). However, Patients in all groups showed decreased TEWL and DLQI scores with no significant difference. No clinically relevant changes in laboratory values were observed except IL-17. There was significant decline of IL-17 in all groups (p<0.05). Inter-group analysis showed no significant difference. No serious adverse event was observed.
Speaker Presentations
Speaker PPTs Click Here